Full Text View
Tabular View
No Study Results Posted
Related Studies
Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer
This study is ongoing, but not recruiting participants.
Study NCT00543842   Information provided by M.D. Anderson Cancer Center

First Received on October 11, 2007.   Last Updated on November 15, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Rectal Cancer
Additional conditions recognized in this trial
Rectal Neoplasms
More general conditions related to this trial
Colorectal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Interventions listed in this trial
Bevacizumab
Capecitabine
Erlotinib
Radiation Therapy
Surgery
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Fluorouracil
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Genentech


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services